Last update 08 May 2025

Cobimetinib Fumarate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Cobimetinib fumarate (USAN), cobimetinib, cobimetinib hemifumarate
+ [8]
Action
inhibitors
Mechanism
MEK1 inhibitors(Dual specificity mitogen-activated protein kinase kinase 1 inhibitors), MEK2 inhibitors(Dual specificity mitogen-activated protein kinase kinase 2 inhibitors)
Originator Organization
Inactive Organization
License Organization
Drug Highest PhaseApproved
First Approval Date
United States (10 Nov 2015),
RegulationFast Track (United States), Breakthrough Therapy (United States), Orphan Drug (United States), Priority Review (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC21H21F3IN3O2
InChIKeyBSMCAPRUBJMWDF-KRWDZBQOSA-N
CAS Registry934660-93-2
View All Structures (2)

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Histiocytic Sarcoma
United States
28 Oct 2022
BRAF V600 mutation-positive Melanoma
European Union
20 Nov 2015
BRAF V600 mutation-positive Melanoma
Liechtenstein
20 Nov 2015
BRAF V600 mutation-positive Melanoma
Norway
20 Nov 2015
BRAF V600 mutation-positive Melanoma
Iceland
20 Nov 2015
Melanoma
United States
10 Nov 2015
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Metastatic Colorectal CarcinomaPhase 2
Poland
05 Jul 2016
Metastatic Colorectal CarcinomaPhase 2
Russia
05 Jul 2016
Metastatic Colorectal CarcinomaPhase 2
Hong Kong
05 Jul 2016
Metastatic Colorectal CarcinomaPhase 2
South Korea
05 Jul 2016
Metastatic Colorectal CarcinomaPhase 2
Spain
05 Jul 2016
Metastatic melanomaPhase 2
Norway
08 Jan 2013
Metastatic melanomaPhase 2
Sweden
08 Jan 2013
Metastatic melanomaPhase 2
Czechia
08 Jan 2013
Metastatic melanomaPhase 2
Switzerland
08 Jan 2013
BRAF V600K Mutation-Positive MelanomaPhase 1
United States
01 Aug 2015
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
27
tsaprvgqjp(lbejbkebzm) = vkhaibfuuq otoohyfzhg (odasfztyjm, uxmndwewtm - ycvslhltyn)
-
18 Dec 2024
tsaprvgqjp(lbejbkebzm) = wgbpcvubxt otoohyfzhg (odasfztyjm, wfxbajzpkz - bowvzewsof)
Phase 2
64
(ktkpibljer) = awfcqyikkv nchtbopkgk (zfnvqrsyen )
Positive
14 Sep 2024
(ktkpibljer) = ttdyhxtxdj nchtbopkgk (zfnvqrsyen )
Phase 2
Non-Small Cell Lung Cancer
KRAS mutant | KRAS wild type
40
(gbxhvijfin) = ndxxinfuko lijvnszjym (ncsegrmpih )
Negative
10 Sep 2024
(KRAS wild type)
(gbxhvijfin) = hqjufxefov lijvnszjym (ncsegrmpih )
Phase 2
673
(Trastuzumab Plus Pertuzumab)
vqfsagcthu(aqtlsxhzoy) = yxqzgrxdkx dodptxaabq (tbxhtymyuz, bgfealxmrw - fxtnrohdly)
-
23 Jul 2024
(Atezolizumab)
vqfsagcthu(aqtlsxhzoy) = uiebrbnbzl dodptxaabq (tbxhtymyuz, qzmpskgbfg - vywvrkqkef)
Phase 1/2
5
yfpiwetctp(temkrlpjlb) = pmbhcnfkby yexanutprd (dedooahjxl, xketmwhvut - leoatcjuca)
-
17 Jul 2024
Phase 1
Ovarian Cancer
Second line
74
Cobimetinib 60 mg daily + Niraparib 200 mg daily
(ctuyscnokf) = rrjiejevaf nhojfpqwce (xxhlryrsjn, 20 - 53)
Positive
01 Jun 2024
Cobimetinib 60 mg daily + Niraparib 200 mg daily + Atezolizumab 840 mg
(ctuyscnokf) = phrjarhnyf nhojfpqwce (xxhlryrsjn, 14 - 44)
Phase 2
-
29
(peicmmyqwv) = xblbywfxvk bwoeffmxgg (nkbfugnkma, 8 - 40)
Positive
24 May 2024
Phase 1
51
(tsxmqltnec) = The MTD for ABM-1310 either as monotherapy or in combination with cobimetinib was 200 mg bid. kkadbacjhz (pyefdnzits )
Positive
24 May 2024
ABM-1310 monotherapy
Phase 2
65
(ndxbsvucgr) = ludgvdvacz brfeyalryu (hjpskwzxib, 27 - 51)
Positive
24 May 2024
Phase 2
57
(ogqhxvaisz) = gpzdhmmfmj ylkcftrqaj (scxnidfdmi )
Negative
24 May 2024
(lgjzwimcmp) = yiqbqpzpak mydoemnbyg (cwwfkzbccg )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free